Deferasirox Targets TAOK1 to Induce p53-Mediated Apoptosis in Esophageal Squamous Cell Carcinoma
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26041524 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Boyang Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, School of Basic Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou 450001, China. Hauptthemen laut MEDLINE: Apoptosis, Tumor Suppressor Protein p53, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Provincial Science and Technology Research Project, Postdoctoral Science Foundation of China.
Abstract (Originalsprache)
Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with a poor prognosis and limited effective treatment options. This study investigates the therapeutic potential of Deferasirox (DFO), an iron chelator, in ESCC by targeting TAOK1, an STE20-type kinase implicated in cancer development. We demonstrate that DFO significantly inhibits the proliferation and colony formation of ESCC cells in a dose- and time-dependent manner. Mechanistic investigations reveal that DFO binds directly to TAOK1 and reduces its kinase activity. Proteomics and phosphorylated proteomic sequencing analysis further reveal that TAOK1 knocking down dramatically increased p53-mediated apoptosis. Moreover, the inhibition of TAOK1 by DFO or lenti-virus infection induces apoptosis in ESCC cells, as evidenced by the increased expression of p53, p-p53 (S15), p-p53 (S46), Puma, Noxa, and Bax, and the decreased expression of Bcl-2. Furthermore, in vivo studies using patient-derived xenograft (PDX) mouse models show that DFO treatment significantly reduces tumor volume without observable toxicity. Histological and immunohistochemical analyses confirm the down-regulation of TAOK1 and Ki-67, and the up-regulation of p53 expression in DFO-treated tumors. Our findings suggest that DFO exerts its antitumor effects in ESCC by targeting TAOK1, providing a potential therapeutic strategy for ESCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology, School of Basic Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou 450001, China.
- The First Clinical School of Medicine, Zhengzhou University, Zhengzhou 450001, China.
- China-US (Henan) Hormel Cancer Institute, No. 127, Dongming Road, Jinshui District, Zhengzhou 450008, China.
- Tianjian Laboratory of Advanced Biomedical Sciences, Institute of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- Henan International Joint Laboratory of Cancer Chemoprevention, Zhengzhou University, Zhengzhou 450001, China.
- State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou 450001, China.
ORCID-Profile: Mengqiu Song
Förderung
- Henan Provincial Science and Technology Research Project
- Postdoctoral Science Foundation of China
Zitieren
APA
Li, B., Liu, S., Zhou, X., Hou, D., Jia, H., Tang, R., Zhang, Y., & Song, M. (2025). Deferasirox Targets TAOK1 to Induce p53-Mediated Apoptosis in Esophageal Squamous Cell Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041524
Vancouver
Li B, Liu S, Zhou X, Hou D, Jia H, Tang R, et al. Deferasirox Targets TAOK1 to Induce p53-Mediated Apoptosis in Esophageal Squamous Cell Carcinoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041524
BibTeX
@article{Li2025,
author = {Li, Boyang and Liu, Shihui and Zhou, Xiaowan and Hou, Dongpu and Jia, Huajie and Tang, Rude and Zhang, Yunqing and Song, Mengqiu},
title = {Deferasirox Targets TAOK1 to Induce p53-Mediated Apoptosis in Esophageal Squamous Cell Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26041524}
}
EUVIMED